These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 9293612)

  • 21. Valacyclovir. New indication: for genital herpes, simpler administration.
    Can Fam Physician; 1999 Jul; 45():1698-700, 1703-5. PubMed ID: 10424269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
    Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
    Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
    Fife KH; Warren TJ; Justus SE; Heitman CK;
    Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding.
    Wald A; Selke S; Warren T; Aoki FY; Sacks S; Diaz-Mitoma F; Corey L
    Sex Transm Dis; 2006 Sep; 33(9):529-33. PubMed ID: 16540883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.
    Gupta R; Wald A; Krantz E; Selke S; Warren T; Vargas-Cortes M; Miller G; Corey L
    J Infect Dis; 2004 Oct; 190(8):1374-81. PubMed ID: 15378428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment.
    Leone PA; Trottier S; Miller JM
    Clin Infect Dis; 2002 Apr; 34(7):958-62. PubMed ID: 11880962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
    Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
    Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Valaciclovir: new indications. In genital herpes: simpler administration.
    Prescrire Int; 1999 Feb; 8(39):8-9. PubMed ID: 10557565
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
    DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
    J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
    Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
    J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
    Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
    J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Valacyclovir for the treatment of genital herpes.
    Brantley JS; Hicks L; Sra K; Tyring SK
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):367-76. PubMed ID: 16771614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Valacyclovir in the treatment of facial herpes simplex virus infection.
    Laiskonis A; Thune T; Neldam S; Hiltunen-Back E
    J Infect Dis; 2002 Oct; 186 Suppl 1():S66-70. PubMed ID: 12353189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valaciclovir: a review of its use in the management of herpes zoster.
    Ormrod D; Goa K
    Drugs; 2000 Jun; 59(6):1317-40. PubMed ID: 10882165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double-blind clinical trial.
    Chosidow O; Drouault Y; Garraffo R; Veyssier P;
    Br J Dermatol; 2003 Jan; 148(1):142-6. PubMed ID: 12534609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valaciclovir update.
    Bell AR
    Adv Exp Med Biol; 1999; 458():149-57. PubMed ID: 10549387
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection.
    Bras AP; Sitar DS; Aoki FY
    Can J Clin Pharmacol; 2001; 8(4):207-11. PubMed ID: 11743593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valaciclovir versus aciclovir for the treatment of primary genital herpes simplex: a cost analysis.
    Pinder M; Wright A
    Int J STD AIDS; 2015 Nov; 26(13):971-3. PubMed ID: 25505043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer.
    Glenny AM; Fernandez Mauleffinch LM; Pavitt S; Walsh T
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006706. PubMed ID: 19160295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Valaciclovir].
    Lebrun-Vignes B
    Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):708-15. PubMed ID: 12124513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.